C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.31% | -12.88% | -3.44% | 18.08% | 20.51% |
| Total Depreciation and Amortization | 7.76% | 13.74% | 12.41% | 2.41% | -3.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.55% | 30.83% | 4.21% | 3.59% | 1.27% |
| Change in Net Operating Assets | -482.87% | -518.36% | -838.71% | -461.01% | 210.23% |
| Cash from Operations | -51.47% | -32.63% | -12.34% | 12.53% | 39.01% |
| Capital Expenditure | -237.22% | -73.61% | 82.39% | 83.91% | 89.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.35% | 364.57% | 221.47% | -40.18% | -131.92% |
| Cash from Investing | 83.22% | 360.05% | 233.27% | -39.23% | -132.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 179.79% | -92.46% | -88.74% | -88.58% | -21.80% |
| Repurchase of Common Stock | 0.52% | 7.73% | -92.00% | -92.00% | -76.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.27% | -27.89% | 17.63% | 16.95% | 3.80% |
| Cash from Financing | 178.80% | -92.38% | -87.05% | -86.74% | -0.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.87% | 36.98% | -82.24% | -195.09% | -173.29% |